Enzon Pharmaceuticals, Inc. (ENZN)
OTCMKTS: ENZN · Delayed Price · USD
0.447
+0.080 (21.86%)
Aug 8, 2022 4:00 PM - Market closed
Company Description
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products.
The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1981 |
| IPO Date | Feb 15, 1984 |
| Industry | Biotechnology |
| Sector | Health Care |
| CEO | Andrew Rackear |
Contact Details
Address:
20 Commerce Drive, Suite 135 Cranford, New Jersey 07016 United States | |
| Phone | 732 980 4500 |
| Website | enzon.com |
Stock Details
| Ticker Symbol | ENZN |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0000727510 |
| CUSIP Number | 293904108 |
| ISIN Number | US2939041081 |
| Employer ID | 22-2372868 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard L. Feinstein | Chief Executive Officer, Chief Financial Officer and Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2022 | 3 | Initial statement of beneficial ownership of securities |
| Jun 15, 2022 | 8-K | Current report |
| Apr 26, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Apr 22, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2022 | DEF 14A | Other definitive proxy statements |
| Feb 25, 2022 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
| Nov 5, 2021 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Aug 17, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Aug 5, 2021 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| Jun 8, 2021 | 8-A12G/A | Registration of securities [Section 12(g)] |